Pathology Review Fees | November 2017 CRU Newsletter

By Holly Tiemann

The Duke Biorepository and Precision Pathology Center (BRPC) will institute a new fee schedule beginning January 1, 2018 for Pathology Reviews.    This new fee schedule applies only to Pathology Reviews, which occur early in the IRB Review phase and are not included in BRPC study specific budget teams receive.  Pathology Review fees will be invoiced separately to the study team through CoreResearch@Duke.   Please note Pathology Review fees are waived if a Faculty Pathologist is a listed as a collaborator on the protocol.  The new fee schedule is listed below:

  • New Protocol with No Review Needed:  $0.0  For documentation purposes, an email confirmation will be provided to the study team at the time of determination that Path Review is not needed.  There will be no charge associated with this correspondence. 
  • New Protocol Qualifying for Automatic Approval:   $0.0  For new protocols which require a form but meet the criteria for automatic approval (as delineated on the form) -- a signed Path Review will be provided to the study team at the time of Path Review approval.  There will be no charge associated with the automatic approval process. 
  • New Protocol Full Review:  $468.00  For new protocols which require a full Pathology review as delineated on the form -- a signed Path Review will be provided to the study team at the time of Path Review approval for documentation purposes.  A full protocol review charge will be charged to study-specific fund code (for FY18, this charge will be $468).  All study teams will be invoiced through the CoreResearch@Duke billing system as soon as possible following Path Review approval. 
  • Amended Protocol Full Review: $90.00  All protocol amendments that change the tissue procurement requirements of the study require revised Path Review approvals.  These will be invoiced through the CoreResearch@Duke billing system as a regulatory consultation charge (for FY18, this charge is $90.00).    All study teams will be invoiced through the CoreResearch@Duke billing system as soon as possible following revised Path Review approval.

Share